NCT06881784Phase 3Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Study sponsor: Revolution Medicines, Inc. · RVMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12-01Estimated
Enrollment · participants590Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population. After: Measure: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population.

Planned enrollment increased by 170 participants

Before: 420 participants (planned). After: 590 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview